Jane Street Group LLC Increases Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Jane Street Group LLC lifted its position in Bicycle Therapeutics plc (NASDAQ:BCYC) by 35.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,180 shares of the company’s stock after acquiring an additional 5,310 shares during the quarter. Jane Street Group LLC’s holdings in Bicycle Therapeutics were worth $457,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Natixis Advisors LLC purchased a new stake in Bicycle Therapeutics in the second quarter worth $261,000. TD Asset Management Inc raised its position in Bicycle Therapeutics by 76.7% during the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after purchasing an additional 42,200 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after buying an additional 161,100 shares during the period. L & S Advisors Inc grew its holdings in Bicycle Therapeutics by 16.1% during the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after acquiring an additional 8,075 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Bicycle Therapeutics during the 2nd quarter valued at about $206,000. 86.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BCYC has been the topic of several research reports. Stephens began coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price objective on the stock. B. Riley lowered their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. JMP Securities dropped their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Insider Activity

In other news, CTO Michael Skynner sold 3,287 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $46,313.83. Following the sale, the chief technology officer now directly owns 124,658 shares of the company’s stock, valued at approximately $1,756,431.22. The trade was a 2.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,933 shares of company stock valued at $549,501. 8.50% of the stock is currently owned by insiders.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $14.88 on Tuesday. Bicycle Therapeutics plc has a 1-year low of $12.17 and a 1-year high of $28.67. The company has a market cap of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92. The stock’s 50 day simple moving average is $19.27 and its 200-day simple moving average is $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the prior year, the company earned ($1.26) EPS. Bicycle Therapeutics’s revenue was down 50.0% compared to the same quarter last year. On average, equities research analysts anticipate that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.